A gene therapy for a rare, genetic eye disorder has been selected by the US Food and Drug Administration for its Regenerative Medicine Advanced Therapy Designation in recognition of the product’s potential to treat an unmet medical need. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Regulation & Policy
